Interest income, net for the fiscal year ended June 30, 2007, was $1,226,099 as compared to $350,380 for the fiscal year ended June 30, 2006. The increase in interest income, net of $875,719 primarily resulted from increased cash balances due to the November 2006 private placement and the upfront payment received from Elan.
Recovery of future income taxes for the year ended June 30, 2007 increased by $1,631,901 or 149% to a recovery of $2,729,422 as compared to a recovery of $1,097,521 for the year ended June 30, 2006. The majority of the increase in recovery of future income taxes for fiscal 2007 is due to the recognition of future income tax assets resulting from the amalgamation of Ellipsis Neurotherapeutics Inc., 1255205 Ontario Inc., 1255206 Ontario Inc. and Waratah Pharmaceuticals Inc. As a result of the amalgamation, the Company has adjusted the valuation allowance on future income tax assets and has recognized a future income tax asset to the extent of offsetting future income tax liabilities of the amalgamated entity. Additional future income tax recovery also arose from changes in temporary differences.
Transition is a biopharmaceutical company, developing novel
therapeutics for disease indications with large markets. Transition's lead
products include ELND-005/AZD-103 for the treatment of Alzheimer's disease
and regenerative therapies E1-I.N.T.(TM) and GLP1-I.N.T.(TM) for the
treatment of diabetes. Transition has an emerging pipeline of preclinical
drug candidates developed using its proprietary drug discovery engine.
Transition's shares are listed on the NASDAQ under the symbol "TTHI" and
the Toronto Stock Exchange under the symbol "TTH". For additional
information about the company, please visit ht
|SOURCE Transition Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved